Stay updated on Daratumumab in Newly Diagnosed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Newly Diagnosed Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab in Newly Diagnosed Multiple Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to include a Phase II study on Multiple Myeloma, detailing a 4-drug combination treatment involving dexamethasone, daratumumab, carfilzomib, and lenalidomide, with Janssen Pharmaceuticals as a collaborator. The previous version's detailed description of the study's purpose and inclusion/exclusion criteria has been removed.SummaryDifference39%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Daratumumab in Newly Diagnosed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Newly Diagnosed Multiple Myeloma Clinical Trial page.